Biomimetic aggrecan reduces cartilage extracellular matrix from degradation and lowers catabolic activity in ex vivo and in vivo models

Shaili Sharma, Aeju Lee, Kuiwon Choi, Kwangmeyung Kim, Inchan Youn, Stephen B. Trippel, Alyssa Panitch

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Aggrecan, a major macromolecule in cartilage, protects the extracellular matrix (ECM) from degradation during the progression of osteoarthritis (OA). However, aggrecan itself is also susceptible to proteolytic cleavage. Here, the use of a biomimetic proteoglycan (mAGC) is presented, which functionally mimics aggrecan but lacks the known cleavage sites, protecting the molecule from proteolytic degradation. The objective of this study is to test the efficacy of this molecule in ex vivo (human OA synovial fluid) and in vivo (Sprague-Dawley rats) osteoarthritic models. These results indicate that mAGC's may protect articular cartilage against the loss of key ECM components, and lower catabolic protein and gene expression in both models. This suppression of matrix degradation has the potential to provide a healthy environment for tissue repair.

Original languageEnglish (US)
Pages (from-to)1228-1237
Number of pages10
JournalMacromolecular Bioscience
Volume13
Issue number9
DOIs
StatePublished - Sep 1 2013

Keywords

  • Aggrecan
  • Biomimetics
  • Cartilage
  • Extracellular matrix
  • Proteolytic enzymes

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomaterials
  • Polymers and Plastics
  • Materials Chemistry

Fingerprint Dive into the research topics of 'Biomimetic aggrecan reduces cartilage extracellular matrix from degradation and lowers catabolic activity in ex vivo and in vivo models'. Together they form a unique fingerprint.

  • Cite this